UY28387A1 - Compuestos novedosos - Google Patents
Compuestos novedososInfo
- Publication number
- UY28387A1 UY28387A1 UY28387A UY28387A UY28387A1 UY 28387 A1 UY28387 A1 UY 28387A1 UY 28387 A UY28387 A UY 28387A UY 28387 A UY28387 A UY 28387A UY 28387 A1 UY28387 A1 UY 28387A1
- Authority
- UY
- Uruguay
- Prior art keywords
- new compounds
- compounds
- prodrug
- solvate
- therapy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0301922A SE0301922D0 (sv) | 2003-06-27 | 2003-06-27 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY28387A1 true UY28387A1 (es) | 2005-01-31 |
Family
ID=27656653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY28387A UY28387A1 (es) | 2003-06-27 | 2004-06-25 | Compuestos novedosos |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US7485644B2 (https=) |
| EP (1) | EP1644340B1 (https=) |
| JP (1) | JP4701167B2 (https=) |
| KR (1) | KR20060026440A (https=) |
| CN (2) | CN102229589A (https=) |
| AR (1) | AR044931A1 (https=) |
| AT (1) | ATE414063T1 (https=) |
| AU (1) | AU2004251104B2 (https=) |
| BR (1) | BRPI0411929A (https=) |
| CA (1) | CA2529468A1 (https=) |
| CO (1) | CO5650254A2 (https=) |
| CY (1) | CY1108757T1 (https=) |
| DE (1) | DE602004017733D1 (https=) |
| DK (1) | DK1644340T3 (https=) |
| ES (1) | ES2315675T3 (https=) |
| HR (1) | HRP20090009T3 (https=) |
| IL (1) | IL172615A0 (https=) |
| IS (1) | IS8257A (https=) |
| MX (1) | MXPA05013460A (https=) |
| MY (1) | MY138680A (https=) |
| NO (1) | NO20060444L (https=) |
| NZ (1) | NZ544208A (https=) |
| PL (1) | PL1644340T3 (https=) |
| PT (1) | PT1644340E (https=) |
| RU (1) | RU2351595C2 (https=) |
| SA (1) | SA04250224B1 (https=) |
| SE (1) | SE0301922D0 (https=) |
| SI (1) | SI1644340T1 (https=) |
| TW (1) | TW200524898A (https=) |
| UA (1) | UA81491C2 (https=) |
| UY (1) | UY28387A1 (https=) |
| WO (1) | WO2005000822A1 (https=) |
| ZA (1) | ZA200510458B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0427403D0 (en) | 2004-12-15 | 2005-01-19 | Astrazeneca Ab | Novel compounds I |
| ZA200803327B (en) * | 2005-10-26 | 2009-09-30 | Serono Lab | Sulfonamide derivatives and use thereof for the modulation of metalloproteinases |
| CN101007794B (zh) * | 2006-01-26 | 2010-09-01 | 中国科学院上海药物研究所 | N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途 |
| WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| DK2597084T3 (en) * | 2010-07-08 | 2016-08-15 | Kaken Pharma Co Ltd | N-HYDROXYFORMAMIDE DERIVATIVE AND MEDICINAL CONTAINING SAME |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL200418B1 (pl) * | 1998-01-30 | 2009-01-30 | Darwin Discovery Ltd | Pochodna N-hydroksyformamidu, zawierający ją środek farmaceutyczny i jej zastosowanie |
| GB9919776D0 (en) * | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| EP1187811B1 (en) * | 1999-06-04 | 2007-03-07 | AstraZeneca AB | Inhibitors of metalloproteinases |
| PL365909A1 (en) * | 2000-02-21 | 2005-01-10 | Astrazeneca Ab | Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases |
| GB0119472D0 (en) | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
| MXPA04010555A (es) * | 2002-04-25 | 2005-02-17 | Pharmacia Corp | Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa. |
| ATE411303T1 (de) * | 2003-06-19 | 2008-10-15 | Ucb Pharma Sa | Hydroxamatsulfonamide als inhibitoren von cd23- shedding |
-
2003
- 2003-06-27 SE SE0301922A patent/SE0301922D0/xx unknown
-
2004
- 2004-06-23 PL PL04743053T patent/PL1644340T3/pl unknown
- 2004-06-23 JP JP2006516467A patent/JP4701167B2/ja not_active Expired - Fee Related
- 2004-06-23 HR HR20090009T patent/HRP20090009T3/xx unknown
- 2004-06-23 AU AU2004251104A patent/AU2004251104B2/en not_active Ceased
- 2004-06-23 US US10/561,747 patent/US7485644B2/en not_active Expired - Fee Related
- 2004-06-23 DK DK04743053T patent/DK1644340T3/da active
- 2004-06-23 BR BRPI0411929-0A patent/BRPI0411929A/pt not_active IP Right Cessation
- 2004-06-23 WO PCT/GB2004/002702 patent/WO2005000822A1/en not_active Ceased
- 2004-06-23 KR KR1020057024709A patent/KR20060026440A/ko not_active Abandoned
- 2004-06-23 ES ES04743053T patent/ES2315675T3/es not_active Expired - Lifetime
- 2004-06-23 EP EP04743053A patent/EP1644340B1/en not_active Expired - Lifetime
- 2004-06-23 AT AT04743053T patent/ATE414063T1/de active
- 2004-06-23 PT PT04743053T patent/PT1644340E/pt unknown
- 2004-06-23 NZ NZ544208A patent/NZ544208A/en unknown
- 2004-06-23 UA UAA200511723A patent/UA81491C2/uk unknown
- 2004-06-23 CA CA002529468A patent/CA2529468A1/en not_active Abandoned
- 2004-06-23 DE DE602004017733T patent/DE602004017733D1/de not_active Expired - Lifetime
- 2004-06-23 SI SI200430979T patent/SI1644340T1/sl unknown
- 2004-06-23 CN CN201110103041XA patent/CN102229589A/zh active Pending
- 2004-06-23 MX MXPA05013460A patent/MXPA05013460A/es active IP Right Grant
- 2004-06-23 RU RU2005141058/04A patent/RU2351595C2/ru not_active IP Right Cessation
- 2004-06-23 CN CN2004800182447A patent/CN1812974B/zh not_active Expired - Fee Related
- 2004-06-25 UY UY28387A patent/UY28387A1/es unknown
- 2004-06-25 MY MYPI20042517A patent/MY138680A/en unknown
- 2004-06-25 TW TW093118692A patent/TW200524898A/zh unknown
- 2004-06-25 AR ARP040102258A patent/AR044931A1/es not_active Application Discontinuation
- 2004-07-14 SA SA04250224A patent/SA04250224B1/ar unknown
-
2005
- 2005-12-15 IL IL172615A patent/IL172615A0/en unknown
- 2005-12-22 ZA ZA200510458A patent/ZA200510458B/xx unknown
- 2005-12-27 CO CO05130352A patent/CO5650254A2/es not_active Application Discontinuation
-
2006
- 2006-01-23 IS IS8257A patent/IS8257A/is unknown
- 2006-01-27 NO NO20060444A patent/NO20060444L/no not_active Application Discontinuation
-
2009
- 2009-01-19 CY CY20091100064T patent/CY1108757T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY29087A1 (es) | Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico | |
| PA8591701A1 (es) | Derivados de pirrolopirimidina | |
| GT200600518A (es) | Derivados de pirimidina | |
| PA8577101A1 (es) | Nuevos derivados de glicosido de tiofeno, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos | |
| UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| UY29825A1 (es) | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones | |
| CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| ECSP066312A (es) | Derivados piridilo y su uso como agentes terapéuticos | |
| UY28510A1 (es) | Compuestos quimicos | |
| ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| ECSP066313A (es) | Derivados de la piridazina y su uso como agentes terapéuticos | |
| ECSP066315A (es) | Derivados de la piridazina y su uso como agentes terapéuticos | |
| CO6251364A2 (es) | Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k | |
| UY28572A1 (es) | Compuestos novedosos | |
| SV2008001369A (es) | Benzimidazoles | |
| ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
| ECSP088099A (es) | Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas | |
| UY30327A1 (es) | Nuevos compuestos ii | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| UY31334A1 (es) | 3a,4,5,6,7,7a-hexahidro-3h-benzoimidazol y derivaods de 3a, 4,5,6,,7,7a-hexahidro-3-indol, enantiómeros, diastereoisómeros, sales farmacéuticamente aceptadas, mezclas, composiciones, preparaciones y aplicaciones de las mismas | |
| UY29002A1 (es) | Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia | |
| UY31141A1 (es) | Compuestos de piperidina y sus usos | |
| UY30393A1 (es) | Derivados sustituidos de la 1-piperidin-1-il-1,3-dihidro-2h-benzimidazol-2-ona, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones | |
| UY29234A1 (es) | Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones. | |
| UY29370A1 (es) | Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones |